Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer

NCT02580448 is registered in ClinicalTrials.gov with Innocrin Pharmaceutical as lead sponsor.

NCT NCT02580448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02580448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Lead sponsor
Innocrin Pharmaceutical
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2015
Completion date
January 31, 2019
Enrollment
175 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, cancer of the breast, er+ breast cancer, male breast cancer, metastatic breast cancer, triple negative breast cancer